ISA Pharmaceuticals featured in June edition of MedNous 27 Jun 2018 Previous ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer Next ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 plus Nivolumab in JAMA Oncology
